Fiduciary Trust Co. reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 16.0% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 131,788 shares of the biopharmaceutical company’s stock after selling 25,191 shares during the quarter. Fiduciary Trust Co.’s holdings in Gilead Sciences were worth $9,328,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also modified their holdings of GILD. Strategic Advisors LLC bought a new position in shares of Gilead Sciences during the 1st quarter worth approximately $1,041,000. Point View Wealth Management Inc. boosted its stake in shares of Gilead Sciences by 21.4% during the 1st quarter. Point View Wealth Management Inc. now owns 7,851 shares of the biopharmaceutical company’s stock worth $533,000 after acquiring an additional 1,385 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Gilead Sciences by 9.8% during the 1st quarter. Bank of New York Mellon Corp now owns 30,570,798 shares of the biopharmaceutical company’s stock worth $2,076,368,000 after acquiring an additional 2,727,063 shares during the period. Clean Yield Group boosted its stake in shares of Gilead Sciences by 16.4% during the 1st quarter. Clean Yield Group now owns 46,253 shares of the biopharmaceutical company’s stock worth $3,142,000 after acquiring an additional 6,510 shares during the period. Finally, Ray Gerald L & Associates Ltd. boosted its stake in shares of Gilead Sciences by 11.0% during the 1st quarter. Ray Gerald L & Associates Ltd. now owns 75,025 shares of the biopharmaceutical company’s stock worth $5,096,000 after acquiring an additional 7,445 shares during the period. Institutional investors own 74.62% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This report was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://ledgergazette.com/2017/11/13/gilead-sciences-inc-gild-holdings-decreased-by-fiduciary-trust-co-2.html.
Gilead Sciences, Inc. (GILD) opened at $73.77 on Monday. Gilead Sciences, Inc. has a fifty-two week low of $63.76 and a fifty-two week high of $86.27. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. The stock has a market capitalization of $96,363.46, a PE ratio of 7.70, a price-to-earnings-growth ratio of -1.24 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. During the same quarter in the prior year, the firm earned $2.75 EPS. The business’s revenue for the quarter was down 13.2% compared to the same quarter last year. equities analysts forecast that Gilead Sciences, Inc. will post 8.53 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be issued a $0.52 dividend. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.82%. Gilead Sciences’s payout ratio is presently 23.69%.
In other news, insider John C. Martin sold 73,333 shares of the stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $75.13, for a total value of $5,509,508.29. Following the completion of the sale, the insider now owns 3,070,099 shares of the company’s stock, valued at $230,656,537.87. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total value of $1,122,300.00. Following the completion of the sale, the executive vice president now directly owns 77,363 shares of the company’s stock, valued at approximately $5,788,299.66. The disclosure for this sale can be found here. In the last ninety days, insiders sold 446,819 shares of company stock valued at $36,269,486. Insiders own 1.30% of the company’s stock.
Several research analysts have recently commented on the company. Mizuho lifted their target price on Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, November 8th. Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a research note on Friday, October 27th. BMO Capital Markets reduced their target price on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating for the company in a research note on Friday, October 27th. J P Morgan Chase & Co set a $85.00 target price on Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Finally, Leerink Swann lifted their target price on Gilead Sciences from $84.00 to $85.00 and gave the stock a “market perform” rating in a research note on Thursday, October 19th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Gilead Sciences presently has a consensus rating of “Buy” and an average price target of $85.92.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.